Sign inJoin waitlistJoin the waitlist

Robert Rosenson

Director, Advanced Fellowship in Preventive Cardiology · Icahn School of Medicine at Mount Sinai

Credentials: · · · · · ·

History

Icahn School of Medicine at Mount Sinai
Present

Brigham and Women's Hospital
1986–1989
Internal Medicine
1983–1986
Tulane University School of Medicine
1979–1983

Research

ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the…
Journal of the American College of Cardiology · 2009 · 1,271 citations
ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the…
Circulation · 2009 · 872 citations
Antiatherothrombotic properties of statins: implications for cardiovascular event reduction
Review · JAMA · 1998 · First of 2 authors · 831 citations

MF
Michael Farkouh
36 papers
Vera Bittner
36 papers
SG
Sascha Goonewardena
28 papers
Monika Safford
27 papers
Christie Ballantyne
24 papers
Todd Brown
24 papers
Elizabeth Jackson
15 papers
Cindy Grines
14 papers
Deepak Bhatt
14 papers
Kiran Musunuru
14 papers
RD
Ricardo Dent-Acosta
14 papers
RP
Robert Pordy
14 papers

Grants

Use of High Density Lipoprotein Proteome in the Prediction of Cognitive Impairment and Alzheimer's Disease: (REGARDS)
National Institute on Aging · R01
Contact PI · $2.5M · Icahn School of Medicine at Mount Sinai
2019–2024

Clinical trials

The Effects of Evolocumab in Patients With Diabetes and Atherosclerotic Vascular Disease
Principal investigator · Completed · Phase 4
Robert Rosenson
2019–2021
Comparative Efficacy of Ticagrelor Versus Aspirin on Blood Viscosity in Peripheral Artery Disease Patients With Type 2 Diabetes
Principal investigator · Completed · Phase 3
Icahn School of Medicine at Mount Sinai
2015–2018
Effects of Micronized Fenofibrate on Fasting and Postprandial Lipoproteins, Inflammatory Mediators and Thrombosis
Principal investigator · Completed
University of Michigan
2001–2002
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
Site PI · Recruiting · Phase 3
Novartis Pharmaceuticals
2026–2030